MPN

MPN (plural MPNs)

1. (cytology, microbiology) Initialism of Most Probable Number.
   • 1982 October, F. J. Bolton, P. M. Hinchliffe, D. Coates and L. Robertson, “A Most Probable Number Method for Estimating Small Numbers of Campylobacters in Water”, in The Journal of Hygiene, volume 89, number 2, →JSTOR, pages 185-190:

     A most probable number (MPN) method capable of estimating as campylobacters per 100 ml of water is described. The method gave results close to those obtained by the viable count method of Miles, Misra & Irwin (1938) with graded suspensions of Campylobacter jejuni.

2. (oncology) Initialism of myeloproliferative neoplasm.
   • 2025 September 8, Tony Berberabe, “Azacitidine, Ruxolitinib Pairing Highlighted in Advanced MPN”, in Targeted Oncology‎^[1], archived from the original on 10 September 2025:

     Findings from an observational retrospective study1 evaluating the outcome of patients with accelerated‐phase or blast‐phase myeloproliferative neoplasms (AP/BP-MPNs) who received azacitidine monotherapy or in combination revealed a median overall survival (OS) of 8.04 months after a median follow-up of 15 months, particularly for those without high-risk genetic features. Overall, OS was lower in patients with BP vs AP (6.24 vs 18.0 months; P = .03), complex karyotype (6.0 vs 13.08 months; P =.005), and TP53 mutation (8.0 vs 11.0 months; P =.009), respectively.

3. (oncology) Initialism of myelodysplastic syndrome.
   • 2025 September 5, Ryan Scott, “What Does a Blood Cancer Diagnosis Mean?”, in Cure‎^[2], archived from the original on 10 September 2025:

     In an MPN, the bone marrow overproduces one or more types of blood cells like red blood cells, white blood cells, or platelets. This can lead to conditions like Polycythemia Vera, which involves too many red blood cells, or essential thrombocythemia, which is an overproduction of platelets. These are often chronic diseases that progress slowly.